drugset / Trial / NCT05485779

SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects

NCT05485779 ↗

Phase 1 Completed 66 enrolled AQILION AB
RandomizedSequentialDouble-blindTreatment

Summary

The principal aim of this study is to obtain safety and tolerability data when AQ280 is administered orally as single and multiple doses to healthy subjects. This information, together with the pharmacokinetic (PK) data, will help establish the doses and dosing regimen suitable for future studies in patients.

Timeline

Start
2022-07-20
Primary completion
2023-07-10
Completion
2023-07-10

Drugs

EvaluationDrugModalityDoseRoute
Subject AQ280 Unknown 3 mg Oral